EUVIMEDEUVIMED entdecken
Crossref

Optimization and Clinical-Scale Production of GMP-Grade NK Cells for Adoptive Cancer Immunotherapy

P. Davies, S. Johnson, R. Miller

Asian Journal of Current Research in Clinical Cancer · 2022

DOI: 10.51847/0mz81d1ojh ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asian Journal of Current Research in Clinical Cancer, 2022. Verfasst von P. Davies und 2 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Natural killer (NK) cells are a promising avenue for cancer immunotherapy, but efficient clinical-scale production remains challenging. Here, we present an optimized protocol for the activation and expansion of NK cells (NKAE) and its validation under clinical-grade conditions. NK cells were expanded from either total peripheral blood mononuclear cells (PBMCs) or CD45RA+ subsets using irradiated K562 feeder cells expressing IL15-41BBL or IL21-41BBL, with culture media including RPMI-1640, SCGM,

Zitieren

APA

Davies, P., Johnson, S., & Miller, R. (2022). Optimization and Clinical-Scale Production of GMP-Grade NK Cells for Adoptive Cancer Immunotherapy. Asian Journal of Current Research in Clinical Cancer. https://doi.org/10.51847/0mz81d1ojh

Vancouver

Davies P, Johnson S, Miller R. Optimization and Clinical-Scale Production of GMP-Grade NK Cells for Adoptive Cancer Immunotherapy. Asian Journal of Current Research in Clinical Cancer. 2022. doi:10.51847/0mz81d1ojh

BibTeX
@article{Davies2022,
  author = {Davies, P. and Johnson, S. and Miller, R.},
  title = {Optimization and Clinical-Scale Production of GMP-Grade NK Cells for Adoptive Cancer Immunotherapy},
  journal = {Asian Journal of Current Research in Clinical Cancer},
  year = {2022},
  doi = {10.51847/0mz81d1ojh}
}
Kostenlos starten →